Adma Biologics Inc
ADMA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.4B
Close$
$7.07
34.1% downside
Current Fair Value
34.1% downsideOvervalued by 34.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.40 Billion |
|---|---|
| Enterprise Value | $2.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.62 |
| Beta | 0.77 |
| Outstanding Shares | 228,232,503 |
Return
| Return on Equity | 41.39% |
|---|---|
| Return on Assets | 24.69% |
| Return on Invested Capital | 37.17% |
Valuation & Multiples
| P/E Ratio | 14.39 |
|---|---|
| PEG | 136.66 |
| Price to Sales | 5.37 |
| Price to Book Ratio | 10.73 |
| Enterprise Value to Revenue | 4.82 |
| Enterprise Value to EBIT | 10.92 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.5 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$149.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.20
Average shareholder expectationRevenue Estimate
$138.11 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 65.57% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 89.97% |
|---|---|
| Total Invested | $576,343▼ 99.97% |
| Investors Holding | 10▼ 331.00% |
ESG Score
No data